Definium Therapeutics, Inc. (DFTX) stock
DFTXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$29.38−0.78 (-2.59%)
Close on Nov 17, 2026Market cap $3.95BP/E –Yield –
Definium Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Definium Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$227.54M. For fiscal 2025 it was -$166.31M. The highest annual figure on record is -$33.03M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$166.31M | – |
| FY2024 | Dec 31, 2024 | -$103.92M | – |
| FY2023 | Dec 31, 2023 | -$93.87M | – |
| FY2022 | Dec 31, 2022 | -$66.33M | – |
| FY2021 | Dec 31, 2021 | -$93.85M | – |
| FY2020 | Dec 31, 2020 | -$33.03M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$75.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$59.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$47.58M | – |
| Q3 FY2025 | Sep 30, 2025 | -$45.67M | – |
| Q2 FY2025 | Jun 30, 2025 | -$40.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$32.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$32.46M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.79M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.46M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.20M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$21.62M | – |
| Q2 FY2023 | Jun 30, 2023 | -$29.18M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.86M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.90M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.98M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.94M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.51M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$45.22M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.85M | – |
See a number that looks wrong?